Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance
- 433 Downloads
The overexpression of ATP-binding cassette (ABC) transporters is one of the main causes of multi-drug resistance (MDR) which represents a major obstacle to the success of cancer chemotherapy. In this study, we examined the effect of BIBF 1120, an inhibitor of vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs) and fibroblast growth factor receptors (FGFRs) tyrosine kinases, on the reversal of multidrug resistance in vitro.
The doxorubicin and rhodamine 123 retention assay was performed by flowcytometry. Western blot were employed to identify ABCB1 expression level and the effect of BIBF 1120 on the blockade of Akt and ERK1/2 phosphorylation. The expression of mdr1 mRNA was determined by RT-PCR analysis. The ATPase activity of ABCB1 was investigated using Pgp-Glo™ assay systems.
BIBF 1120 significantly enhanced the cytotoxicity of doxorubicin and paclitaxel and increased the accumulation of ABCB1 substrates in ABCB1-overexpressing cancer cells, whereas it had no effect on the parental cells. On the other hand, BIBF 1120 did not alter the cytotoxicity of non-ABCB1 substrates and was unable to reverse ABCC1 or ABCG2-mediated MDR. Furthermore, BIBF 1120 inhibited the ATPase activity of ABCB1 in a concentration-dependent manner. However, no detectable alteration on the expression level of mdr1 mRNA or ABCB1 protein was identified in ABCB1-overexpressing cancer cells by different treatments of BIBF 1120. Interestly, total and phosphorylated forms of AKT and ERK1/2 were not inhibited by BIBF 1120 at the reversal concentrations.
Our results suggest that BIBF 1120 is capable of overcoming ABCB1-mediated drug resistance by inhibiting ABCB1 function, which may have clinical significance for BIBF 1120 combinational treatment of certain resistant cancers.
KeywordsBIBF 1120 Multidrug resistance ATP-binding cassette transporters ABCB1/P-glycoprotein
We thank Drs S.E. Bates and R.W. Robey (National Cancer Institute, NIH) for the ABCG2 expressing cell line S1-M1-80 and their parental sensitive cell line S1. The work was supported by grants from China National Natural Sciences Foundation No. 81072669 and No. 81061160.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
- 8.G. Szakacs, J.P. Annereau, S. Lababidi, U. Shankavaram, A. Arciello, K.J. Bussey, W. Reinhold, Y. Guo, G.D. Kruh, M. Reimers, J.N. Weinstein, M.M. Gottesman, Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6, 129–137 (2004)PubMedCrossRefGoogle Scholar
- 15.F. Hilberg, G.J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, U. Tontsch-Grunt, P. Garin-Chesa, G. Bader, A. Zoephel, J. Quant, A. Heckel, W.J. Rettig, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774–4782 (2008)PubMedCrossRefGoogle Scholar
- 17.C.L. Dai, A.K. Tiwari, C.P. Wu, X.D. Su, S.R. Wang, D.G. Liu, C.R. Ashby Jr., Y. Huang, R.W. Robey, Y.J. Liang, L.M. Chen, C.J. Shi, S.V. Ambudkar, Z.S. Chen, L.W. Fu, Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 68, 7905–7914 (2008)PubMedCrossRefGoogle Scholar
- 18.T. Kitazaki, M. Oka, Y. Nakamura, J. Tsurutani, S. Doi, M. Yasunaga, M. Takemura, H. Yabuuchi, H. Soda, S. Kohno, Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49, 337–343 (2005)PubMedCrossRefGoogle Scholar
- 19.Z. Shi, X.X. Peng, I.W. Kim, S. Shukla, Q.S. Si, R.W. Robey, S.E. Bates, T. Shen, C.R. Ashby Jr., L.W. Fu, S.V. Ambudkar, Z.S. Chen, Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 67, 11012–11020 (2007)PubMedCrossRefGoogle Scholar
- 21.L.S. Zheng, F. Wang, Y.H. Li, X. Zhang, L.M. Chen, Y.J. Liang, C.L. Dai, Y.Y. Yan, L.Y. Tao, Y.J. Mi, A.K. Yang, K.K. To, L.W. Fu, Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS ONE 4, e5172 (2009)PubMedCrossRefGoogle Scholar
- 22.C.L. Dai, Y.J. Liang, Y.S. Wang, A.K. Tiwari, Y.Y. Yan, F. Wang, Z.S. Chen, X.Z. Tong, L.W. Fu, Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 279, 74–83 (2009)PubMedCrossRefGoogle Scholar
- 23.F. Hilberg, I. Brandstetter, Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy: C7-03, Journal of Thoracic Oncology 2 (2007) S380 310.1097/1001.JTO.0000283231.0000276336.0000283201.Google Scholar
- 24.A. du Bois, J. Huober, P. Stopfer, J. Pfisterer, P. Wimberger, S. Loibl, V.L. Reichardt, P. Harter, A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann. Oncol. 21, 370–375 (2010)PubMedCrossRefGoogle Scholar
- 25.M. Reck, R. Kaiser, C. Eschbach, M. Stefanic, J. Love, U. Gatzemeier, J. von Pawel, Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC): B1-03, Journal of Thoracic Oncology 2 (2007) S333-S334 310.1097/1001.JTO.0000283141.0000268423.c0000283145.Google Scholar
- 28.P.M. Tang, D.M. Zhang, N.H. Xuan, S.K. Tsui, M.M. Waye, S.K. Kong, W.P. Fong, K.P. Fung, Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a. Mol. Cancer 8, 56 (2009)PubMedCrossRefGoogle Scholar
- 34.H. Minderman, K.L. O’Loughlin, L. Pendyala, M.R. Baer, VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 10, 1826–1834 (2004)PubMedCrossRefGoogle Scholar
- 40.L. Zahiragic, C. Schliemann, R. Bieker, N.H. Thoennissen, K. Burow, C. Kramer, M. Zuhlsdorf, W.E. Berdel, R.M. Mesters, Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 21, 1310–1312 (2007)PubMedCrossRefGoogle Scholar
- 41.F.J. Giles, W.T. Bellamy, Z. Estrov, S.M. O’Brien, S. Verstovsek, F. Ravandi, M. Beran, P. Bycott, Y. Pithavala, H. Steinfeldt, S.D. Reich, A.F. List, K.W. Yee, The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk. Res. 30, 801–811 (2006)PubMedCrossRefGoogle Scholar
- 45.J. Von Pawel, R. Kaiser, C. Eschbach, M. Stefanic, J. Love, U. Gatzemeier, M. Reck, A double blind phase II study of BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC), J Clin Oncol (Meeting Abstracts) 25, 7635 (2007)Google Scholar
- 49.J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W. Wong, F. Chang, B. Lehmann, D.M. Terrian, M. Milella, A. Tafuri, F. Stivala, M. Libra, J. Basecke, C. Evangelisti, A.M. Martelli, R.A. Franklin, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773, 1263–1284 (2007)PubMedCrossRefGoogle Scholar